StevenLSchoenfeldMD

Diabetes, Lipid Metabolism

Vice President, Galectin Therapeutics

Dr. Schoenfeld is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Broad-based, international clinical drug development experience with small molecules and biologics.

Specialties: NASH, liver diseases, lysosomal storage diseases (LSD), Oncology, Osteoporosis, Hip Fracture Recovery, Diabetes, Inflammation, and Endocrine Clinical Drug Development.

11 successful 1st IND applications, 9 successful NDAs/MAAs prepared.

University of WashingtonFellowship, Endocrinology, Diabetes, and Metabolism, 1986 - 1989
New York Medical CollegeClass of 1983

William E. Upjohn Medal, “In recognition of Special Accomplishment” Issued by Pfizer, Inc., 2003

PubMed

36 citations
Systematic variation and differences in insulin-autoantibody measurements.
Terence J. Wilkin, Steven L Schoenfeld, Jose-Luis Diaz, Viggo Kruse, Ezio Bonifacio
Diabetes. 1989-02-01
99 citations
Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis: Efficacy and Safety After Seven Years of Treatment
Paul D. Miller, Nelson B. Watts, Angelo A. Licata, Steven T. Harris, Harry K. Genant
The American Journal of Medicine. 1997-12-01
70 citations
Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study.
David K. McCulloch, Leslie J. Klaff, Steven E. Kahn, Steven L Schoenfeld, Carla J. Greenbaum
Diabetes. 1990-05-01